Shares of WAVE Life Sciences (WVE) tumbled 5.22% in intraday trading on Monday following the release of the company's disappointing third-quarter 2025 financial results. The biotechnology firm, which focuses on genetic medicines, reported earnings that fell short of analyst expectations on multiple fronts.

WAVE Life Sciences reported a net loss of $0.32 per share for Q3, slightly wider than the $0.30 loss per share analysts had predicted. While this represents an improvement from the $0.47 loss per share in the same quarter last year, it wasn't enough to meet market expectations. Revenue for the quarter came in at $7.608 million, significantly missing the analyst consensus estimate of $11.130 million, despite showing a substantial increase from the negative revenue reported in the previous year.

The company's financial performance raised concerns among investors, with net income, pretax profit, and income from operations all falling below analyst estimates. WAVE Life Sciences posted a net loss of $53.852 million, compared to the expected loss of $49.2 million. Operating expenses increased to $63.961 million, contributing to the wider-than-anticipated losses. Despite these setbacks, the company maintained a strong cash position of $196.2 million as of September 30, 2025, and expects to fund operations through Q2 of 2027, thanks in part to additional funding received after the quarter's end. As WAVE Life Sciences continues to advance its clinical programs, including WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, investors will be closely monitoring the company's progress and its ability to improve financial performance in upcoming quarters.